Related Experiment Video
Updated: Aug 15, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
Nozomi Hayakawa1, Eiji Kikuchi1
1Department of Urology St Marianna University School of Medicine Japan.
Introduction:
A unique phenomenon of immune therapy is pseudoprogression; however, a definite mechanism and predictive factors remain unclear. We herein report a case of pseudoprogression with avelumab maintenance therapy.
Case Presentation:
A 67-year-old male diagnosed with muscle-invasive bladder cancer with lung metastasis was treated with four cycles of gemcitabine and cisplatin chemotherapy immediately after cystectomy and ileal conduit urinary diversion. The response to cisplatin-based chemotherapy was a stable disease. Avelumab maintenance therapy was started after first-line chemotherapy but was interrupted due to his general fatigue after the third administration of avelumab. At that time, computed tomography (CT) revealed an increased size of lung metastases. Two months after the interruption, avelumab maintenance therapy was restarted. At the end of the seventh dose of avelumab administration, CT showed a dramatic reduction of lung metastatic tumors.
Conclusion:
Pseudoprogression may also occur with avelumab maintenance therapy in metastatic bladder cancer.
More Related Videos
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers